The Generic Drugs Market: 2015 – 2030 - Opportunities, Challenges, Strategies & Forecasts

Release Date: February 2015
Number of Pages: 249
Number of Tables and Figures: 54

Synopsis: A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

For a sample of the report or any further inquiries please contact

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
  • As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
  • In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
  • In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Topics Covered:
The report covers the following topics:
  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2015 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Brand Classification
    • Pure (Non-branded) Generics
    • Branded Generics
    • Super Generics
  • Therapeutic Area
    • Antibiotics
    • Cardiovascular & Hypertension
    • CNS (Central Nervous System)
    • Dermatology
    • Diabetes
    • Gastrointestinal
    • Hormonal Drugs
    • Oncology
    • Pain Relief
    • Respiratory
    • Rheumatology
    • Others
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the generic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for generic cancer drugs?
  • How does regulation impact the adoption of generic drugs?
  • How will branded and super generics impact revenue prospects?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of biologics impact the market?
  • What are the future prospects of approved and non-approved biosimilar drugs?
  • What strategies should generic and innovator drug manufacturers adopt to remain competitive?

    List of Companies Mentioned:
    The following companies and organizations have been reviewed, discussed or mentioned in the report:

    Abbott Laboratories
    ACETO Corporation
    Acino Holding
    Adcock Ingram
    Aesica Pharmaceuticals
    Alexion Pharmaceuticals
    Alfa Wasserman
    AMA (African Medicines Regulatory Agency)
    Amneal Pharmaceuticals
    AMRI (Albany Molecular Research, Inc.)
    Arch Pharmalabs
    ASKA Pharmaceutical Company
    Aspen Holdings
    Astellas Pharma
    Aurobindo Pharma
    Auxilium Pharmaceuticals
    Baxter BioScience
    Baxter International 
    Bayer AG
    BD (Becton, Dickinson and Company)
    BD Rx
    Berlin Chemie
    Biogen Idec
    Biogen Laboratorios
    BMS (Bristol-Myers Squibb)
    Boehringer Ingelheim
    Boots UK
    BPI (Breckenridge Pharmaceutical Inc.) 
    Breckenridge Pharmaceutical 
    Cadila Healthcare (Zydus Cadila)
    Cadila Pharmaceuticals
    CBER (Centre for Biologics Evaluation and Research)
    CDER (Centre for Drug Evaluation and Research) 
    CDSCO (Central Drug Standards and Control Organization, India)
    Cedarburg Pharmaceuticals
    Celgene Corporation
    Celltrion Group
    CFDA (China Food and Drug Administration)
    Chiesi Farmaceutici
    Chugai Pharmaceutical Company
    Claris Injectables
    Claris Lifesciences
    Claris Otsuka
    Coherus BioSciences
    Consort Medical
    Cubist Pharmaceuticals
    Cypress Pharmaceutical
    Daiichi Sankyo
    Daiichi Sankyo Espha 
    Dong-A Pharmaceutical
    Dr. Reddy's Laboratories
    Dusa Pharmaceuticals
    EGA (European Generic Medicines Association) 
    Egis Pharmaceuticals
    Eisai Company
    Eli Lilly and Company
    Elmed Eisai Company 
    EMA (European Medicines Agency)
    Endo International
    Endo Pharmaceuticals 
    ESTEVE Farma 
    ESTEVE Group
    Eurofarma Laboratorios
    FDA (Food and Drug Administration) 
    Ferring Pharmaceuticals
    Forest Laboratories
    Fresenius Kabi
    Fuji Pharma Company
    Fujifilm Corporation 
    Fujifilm Holdings Corporation
    Fujifilm Pharma Company
    Gedeon Richter
    Gedeon Richter PregLem
    GGL (Glenmark Generics Limited) 
    Gilead Sciences
    Glenmark Pharmaceuticals
    Global Pharmaceuticals
    Gruenenthal Group
    GSK (GlaxoSmithKline)
    Guangdong BeiKang Pharmaceutical Company
    Hanmi Pharmaceutical Company
    Health Canada
    Hetero Drugs
    Hikma Pharmaceuticals
    Hi-Tech Pharmacal
    Impax Laboratories
    Impax Pharmaceuticals
    Janssen Pharmaceutica
    Jazz Pharmaceuticals
    JHP Group Holdings
    JHP Pharmaceuticals
    Johnson & Johnson
    JT (Japan Tobacco)
    Kaken Pharmaceutical Company
    Kaneka Corporation
    Kowa Company
    Kowa Health Care America
    Kowa Pharmaceuticals America
    Kowa Research Institute
    Kremers Urban Pharmaceuticals
    Krka (Krka, d. d.)
    Kyowa Hakko Kirin Company
    Kyowa Pharmaceutical Industry Company
    Laboratorios Roemmers
    Leo Pharma
    Les Laboratoires Servier
    Lil Therapeutics
    Lundbeck (H. Lundbeck A/S)
    Maruho Company
    Matrix Laboratories
    Medley Farma
    Meiji Holdings
    Meiji Seika Pharma Company
    Menarini Group
    Merck and Co.
    Merck KGaA
    Merck Serono
    Merz Pharma
    Ministry of Health, Labour and Welfare (Japan)
    Mitsubishi Chemical Holdings Corporation
    Mitsubishi Tanabe Pharma
    Mitsui & Company
    Mitsui Group
    MN (Mustafa Nevzat) Pharma
    Natco Pharma
    Nichi-Iko Pharmaceutical Company
    Nippon Kayaku
    Nippon Shinyaku
    Nipro Pharma Corporation
    Novartis International
    Novo Nordisk
    OLIC (Thailand)
    Ono Pharmaceutical Company
    Orion Corporation
    Osaka Synthetic Chemical Laboratories
    Otsuka Holdings Company
    Otsuka Pharmaceutical Company
    Paladin Labs
    Par Pharmaceutical Companies
    Pensa Dose
    Pensa Pharm
    Perrigo Company
    Pharma Dynamics
    Pierre Fabre (Laboratoires Pierre Fabre)
    Piramal Enterprises
    Piramal Group
    Pliva (Pliva d.d.)
    Prasco Laboratories
    Purdue Pharma
    Qualitest and Vintage Pharmaceuticals
    Ranbaxy Laboratories
    Regeneron Pharmaceuticals
    Rising Pharmaceuticals
    Roche Holding (F. Hoffmann-La Roche)
    Roxane Laboratories
    Salix Pharmaceuticals
    Samsung Bioepis
    Samsung BioLogics 
    Samsung Group
    Sandoz International
    Sanofi-Aventis Nichi-Iko K.K.
    Santen Pharmaceutical Company
    Sawai Pharmaceutical Company
    Seikagaku Corporation
    Sequent Scientific
    Servier Group
    Shionogi & Company
    Somar (Grupo Farmaceutico Somar)
    STADA Arzneimittel
    Strativa Pharmaceuticals
    Strides Arcolab
    Sumitomo Dainippon Pharma Company
    Sun Pharmaceutical Industries
    Supera Farma Laboratorios
    Taisho Pharmaceutical Company
    Taisho Pharmaceutical Holdings Company
    Taisho Pharmaceutical Industries
    Taiyo Pharmaceutical Industry Company
    Takeda Pharmaceutical Company
    Tanabe Seiyaku Hanbai Company
    Taro Pharmaceutical Industries 
    Teijin Pharma 
    Teva Pharmaceutical Industries
    Teva-Kowa Pharma Company
    The Medicines Company
    Torrent Group
    Torrent Pharmaceuticals
    Towa Pharmaceutical Company
    United Therapeutics Corporation
    Valeant Pharmaceuticals International
    Ventana Medical Systems
    Vertex Pharmaceuticals
    West-Ward Pharmaceuticals 
    WHO (World Health Organization)